AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | MicrobiomeTrials← Back to trialsNCT04099966
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-04-01Est. Completion: 2026-12-31
Enrollment target: 20 participants Locations- New York Medical College, Valhalla, New York, United States
Other microbiome trials you might be interested in
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaPediatric CancerPediatric ALL, RelapsedPediatric ALLPediatric ALL, B CellAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaPediatric AMLR/R AMLR/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple LocationsEst. completion Apr 30, 2030
Phase 1
Recruiting
B-AllAcute Lymphoblastic Leukemia
Background:
B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene m…
Bethesda, United StatesEst. completion Jun 30, 2030
Acute Lymphoblastic LeukemiaB-All
Background:
Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy invol…
Bethesda, United StatesEst. completion Jan 31, 2030